|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003864,
umls-concept:C0024554,
umls-concept:C0038013,
umls-concept:C0087111,
umls-concept:C0150312,
umls-concept:C0238694,
umls-concept:C0281481,
umls-concept:C1257890,
umls-concept:C1578536,
umls-concept:C1709709,
umls-concept:C1710133,
umls-concept:C1710263,
umls-concept:C1964257,
umls-concept:C1970124
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-8
|
|
pubmed:abstractText |
To examine clinical characteristics as possible predictors of long-term treatment continuation with adalimumab, etanercept, and infliximab in ankylosing spondylitis (AS) patients who had never taken biologics treated in clinical practice.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
2151-4658
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1362-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20506310-Adult,
pubmed-meshheading:20506310-Antibodies, Monoclonal,
pubmed-meshheading:20506310-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20506310-Cohort Studies,
pubmed-meshheading:20506310-Female,
pubmed-meshheading:20506310-Follow-Up Studies,
pubmed-meshheading:20506310-Humans,
pubmed-meshheading:20506310-Immunoglobulin G,
pubmed-meshheading:20506310-Male,
pubmed-meshheading:20506310-Middle Aged,
pubmed-meshheading:20506310-Osteoarthritis,
pubmed-meshheading:20506310-Predictive Value of Tests,
pubmed-meshheading:20506310-Prospective Studies,
pubmed-meshheading:20506310-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:20506310-Registries,
pubmed-meshheading:20506310-Sex Factors,
pubmed-meshheading:20506310-Spondylitis, Ankylosing,
pubmed-meshheading:20506310-Sweden,
pubmed-meshheading:20506310-Treatment Outcome,
pubmed-meshheading:20506310-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
|
|
pubmed:affiliation |
South Sweden Musculoskeletal Research Centre, Lund University Hospital, Lund University, Sweden. larserik_kristensen@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
